A Decade of Discovery: Celebrating the Ronald M. Loeb Center for Alzheimer’s Disease

Daniel S. Loeb, Mount Sinai Health System Trustee
More than 250 members of the Mount Sinai community and guests recently celebrated the 10th anniversary of the Ronald M. Loeb Center for Alzheimer’s Disease, founded through a generous donation from Mount Sinai Trustee Daniel S. Loeb and his wife, Margaret Munzer Loeb. The center is named for Daniel’s father, who passed away from Alzheimer’s disease (AD).
At the event, Mr. Loeb spoke eloquently about his family’s personal experience with AD and his father’s continued legacy. “I tell his story because this is a disease that doesn’t care how kind you are or how decent you are. It is indiscriminate. And the pain that it’s caused has been severe,” he told the audience, which included leading AD clinicians and researchers. “Ultimately, you are scientists, and you look at the disease, and this is a disease that profoundly affects individuals and their families. Seeing this group come together to make such great progress over the last 10 years is really inspiring. So thank you very much for all you do.”
Today, nearly 7 million Americans have AD, a number that is expected to rise to 13 million by 2050.
The inaugural director of the Loeb Center—whose recruitment was made possible by the family’s philanthropy—is Alison Goate, DPhil, the Jean C. and James W. Crystal Professor of Genomics and Chair of the Department of Genetics and Genomic Sciences. Dr. Goate has recruited a roster of outstanding faculty, and their research on AD and other neurodegenerative diseases—in many cases, groundbreaking—have helped establish it as a preeminent center, known worldwide. Dr. Goate told the attendees that during its first decade, faculty recruits have doubled and National Institutes of Health funding has more than tripled.
Specifically, the Loeb Center has been at the forefront of exploring the role of microglia—the brain’s immune cells—in the development of AD, and by integrating large-scale molecular data from patients using artificial intelligence (AI), they have been able to identify new drug targets. In the next decade, Dr. Goate believes their work holds great potential for uncovering possible new treatments for patients.

Alison M. Goate, DPhil, Director of the Ronald M. Loeb Center for Alzheimer’s Disease; Jean C. and James W. Crystal Professor of Genomics; and Chair of the Department of Genetics and Genomic Sciences
The Loeb Center has become a leading force in translational research, assuring that patients have access to the latest laboratory breakthroughs. These are often made possible by insights gained from its deep repository of human brain tissue, which has yielded new knowledge into the underpinnings of neurodegenerative disease. It has also recently made gains by developing novel blood biomarkers that will help toward improving early diagnosis.
Presentations from faculty also focused on the role of genomics in studying new therapeutics and highlighted their commitment to training the next generation of scientists, featuring a poster presentation from students and trainees who showcased their most recent work. Keynote speaker Jim Ray, PhD, Director of the Belfer Neurodegeneration Center at MD Anderson Cancer Center, spoke compellingly about the challenges of finding a cure for neurodegenerative diseases, but he also projected optimism, saying that research built on AI, genomics, and new disease models holds greater promise.
While the science is complex, it was made clear that the first 10 years of the Loeb Center have been pivotal in making the discoveries that will bring scientists everywhere many steps closer to improved diagnosis and treatment. These advances would not have been possible without the visionary philanthropy of Daniel and Margaret Munzer Loeb, says Dr. Goate, and it is upon that success that the Loeb Center has positioned itself as a leader in the field for decades to come.